Market research
271980.KO Jeil Pharmaceutical Co.,Ltd
KO KRW Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 131B
- P/E ratio
- 14.28
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.6
Profile
Instrument facts
- Exchange
- KO
- Currency
- KRW
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- KR7271980005
- Market cap
- 131B
- P/E ratio
- 14.28
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.6
About
About Jeil Pharmaceutical Co.,Ltd
Jeil Pharmaceutical Co.,Ltd develops and supplies pharmaceutical products primarily in South Korea and internationally. It provides products in the areas of antibiotic, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamine. The company exports its products. Jeil Pharmaceutical Co.,Ltd was founded in 1959 and is headquartered in Seoul, South Korea.
Research context
Jeil Pharmaceutical Co.,Ltd appears in PyInvesting’s Korea Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- KRW
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 271980.KO discussion.
5 years, 6 months ago
Jeil Pharmaceutical Co.,Ltd is currently in a long term downtrend where the price is trading 14.3% below its 200 day moving average.
From a valuation standpoint, the stock is 90.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.8.
Jeil Pharmaceutical Co.,Ltd's total revenue rose by 3.4% to $173B since the same quarter in the previous year.
Its net income has increased by 102.0% to $275M since the same quarter in the previous year.
Finally, its free cash flow grew by 36.4% to $6B since the same quarter in the previous year.
Based on the above factors, Jeil Pharmaceutical Co.,Ltd gets an overall score of 4/5.